Halozyme Therapeutics (HALO) Equity Average (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Equity Average data on file, last reported at $134.2 million in Q1 2026.

• Equity Average for Q1 2026 came in at $134.2 million, down 68.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $134.2 million (down 68.27% YoY), and the FY2025 annual result was $206.3 million, down 7.82% from the prior year.
• Equity Average declined to $134.2 million in Q1 2026 per HALO's latest filing, from $276.4 million in the prior quarter.
• Over five years, Equity Average peaked at $423.0 million in Q1 2025 and troughed at $108.4 million in Q2 2023.
• A 5-year average of $248.8 million and a median of $228.6 million in 2022 frame the typical range for Equity Average.
• The sharpest annual moves came in 2025 and 2026: Equity Average jumped 223.41% in 2025, then sank 68.27% in 2026.
• A 5-year view of Equity Average shows it stood at $133.4 million in 2022, then grew by 24.81% to $166.5 million in 2023, then jumped by 145.21% to $408.3 million in 2024, then plunged by 32.31% to $276.4 million in 2025, then slumped by 51.43% to $134.2 million in 2026.
• Business Quant data shows HALO's Equity Average at $134.2 million in Q1 2026, $276.4 million in Q4 2025, and $418.3 million in Q3 2025.